Weight loss drugs are hiking employer healthcare prices, with 87% saying they expect costs to only go up Employers are saying that popular weight loss drugs are driving up costs for group medical plans to such a degree that theyre considering excluding them from coverage altogether
Viking Therapeutics (VKTX): The High-Risk Wild Card Viking Therapeutics ( NASDAQ:VKTX ) is explicitly the speculative slot
weight-loss hair shedding often confuses women but they differ sharply in causes, timing, and fixes
The direction is clear: more oral options, more receptors engaged per molecule, and broader supply
In addition, small molecule inhibitors including SLC7A11 inhibitor HG106 and GCLC inhibitor buthionine sulfoximine (BSO) were introduced to investigate their effects on ROS, GSH levels and cellular viability in VRK2-KO and VRK2-KD cells, and the results were consistent with the above knockdown experiment (Fig